MyFinsight
Home
Blog
About
Contact
Download
Download image
Net decrease in cash
and cash...
-$12,624K
Collaboration receivable,
current and non-current...
-$24,032K
Net income (loss)
$8,572K
Share-based compensation
$4,325K
Other receivables
-$3,057K
Non-cash lease cost
$1,048K
Impairment of assets
$587K
Prepaid expenses and
other current assets
-$277K
Income taxes payable
$209K
Other long-term
liabilities
$91K
Net cash used in
operating activities
-$12,624K
Canceled cashflow
$42,198K
Deferred revenue -
related party
-$22,074K
Deferred revenue
-$12,587K
Accrued expenses and
other current...
-$12,146K
Accounts payable
-$6,613K
Operating lease
liabilities
-$1,402K
Back
Back
Cash Flow
source: myfinsight.com
Spero Therapeutics, Inc. (SPRO)
Spero Therapeutics, Inc. (SPRO)